Synergistic therapeutic benefit by combining the antibody drug conjugate, depatux-m with temozolomide in pre-clinical models of glioblastoma with overexpression of EGFR by Vaidya, Kedar S., Mitten, Michael J., Zelaya-Lazo, Adelyn L., Oleksijew, Anatol, Alvey, Cory, Falls, Hugh D., Mishra, Sasmita, Palma, Joann, Ansell, Peter, Phillips, Andrew C., Reilly, Edward B., Anderson, Mark, Boghaert, Erwin R.

Get full text